@ugurrnek Avatar @ugurrnek Ugur Oe

Ugur Oe posts on X about $abcl, momentum, upside, $abbv the most. They currently have [---] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [---] #

Followers Line Chart

CreatorRank: [---------] #

CreatorRank Line Chart

Social Influence

Social category influence stocks 32.39% finance 23.94% technology brands 2.82% social networks 1.41% cryptocurrencies 1.41% automotive brands 1.41% vc firms 1.41% currencies 1.41%

Social topic influence $abcl #28, momentum 7.04%, upside 7.04%, $abbv 7.04%, longterm 4.23%, ip 4.23%, stocks 4.23%, ai 4.23%, matter 2.82%, patience 2.82%

Top accounts mentioned or mentioned by @hypergrowth102 @drtomslens @cevikfinance @jare92365776 @bcvalueinvestor @endicottinvests @grok @jrouldz @jackprescottx @jaycarriage @ironman20054 @jinseongeo83473 @jjacobpeterson @alc2022 @sotirou32933 @profkayafinance @ulkser @tuncsatiroglu

Top assets mentioned AbCellera Biologics Inc. (ABCL) AbbVie Inc (ABBV) Palantir Technologies Inc. (PLTR) The Official [--] Coin (67) Morgan Stanley (MS) Tesla, Inc. (TSLA)

Top Social Posts

Top posts by engagements in the last [--] hours

"Bottom line: $ABCL isnt a short-term catalyst play or a momentum name. Its a long-duration platform story where execution + time matter more than headlines. JPM wont guarantee upside but it can reset how institutions frame the story. Patience required"
X Link 2026-01-06T14:20Z [---] followers, [---] engagements

"$ABCL AbCellera Biologics (NASDAQGS:ABCL) delivered a wild ride in its 3-month rolling total returns over the past [--] yearsswinging from jaw-dropping losses to rare bursts of outperformance"
X Link 2026-01-09T06:51Z [---] followers, [----] engagements

"🧵 $ABCL Mega-Thread: JPM [----] Phase [--] [----] roadmap"
X Link 2026-01-27T10:06Z [---] followers, [----] engagements

"📉 Downside vs Upside framing Downside: If data disappoints stock can trade near cash for time Upside: One validated Phase [--] asset narrative shifts from platform to clinical pipeline Thats asymmetric by design"
X Link 2026-01-27T10:06Z [---] followers, [---] engagements

"Bottom line: The market still prices $ABCL like an idea. JPM [----] suggests its becoming an execution story quietly methodically. For long-term holders this is usually the phase before rerating not after"
X Link 2026-01-27T10:06Z [---] followers, [---] engagements

"Strong update $ABCL Im aligned on most of this. Its been a little over a year since I wrote my first article on AbCellera. Heres an update of what Im looking at for the rest of [--] and beyond: A development over the past year has been the companys shift towards prioritizing in-house molecules. They successfully moved https://t.co/zFVPZDd6Cc Its been a little over a year since I wrote my first article on AbCellera. Heres an update of what Im looking at for the rest of [--] and beyond: A development over the past year has been the companys shift towards prioritizing in-house molecules. They"
X Link 2026-02-16T08:13Z [---] followers, [--] engagements

"@BCValueInvestor I like the company. If you check Abcellera LinkedIn youll see many hiring posts. For fundamentals I wrote on X and Reddit positive. Only part is last [--] month and last couple of days. If your strategy is to buy for DCA its OK. Otherwise the signals are just too fresh $ABCL"
X Link 2026-02-10T07:50Z [---] followers, [----] engagements

"635 is the real swing here. If AbCellera validates GPCR targeting with an antibody in Phase [--] thats platform-level proof not just a single-asset win. With 36% of drugs hitting GPCRs (mostly small molecules) even partial validation could unlock a massive long-term opportunity"
X Link 2026-02-16T08:13Z [---] followers, [--] engagements

"575 feels optional to me nice if partnered irrelevant if not. Also watching [---] + the GPCR stack closely. If 2/4 internal programs are GPCR-focused that signals real confidence in the platform. 2026/27 feels like the inflection window. Long and patient. $ABCL"
X Link 2026-02-16T08:13Z [---] followers, [--] engagements

"@EndicottInvests Check $ABCL Abcellera - after 1B revenue [--] years cash burning started. Still 800M cash and completed facility and product ramp ups. Mr. Thiel has an eye on"
X Link 2025-07-26T16:38Z [--] followers, [---] engagements

"@grok says ;) $ABCL @hypergrowth102 Based on current market data (as of July [--] 2025) only [--] from the list have market caps under $2B. Here they are with competitive advantages: [--]. PRME (0.53B): Prime gene editing technology. [--]. OUST (1.21B): Cost-effective digital lidar. [--]. ABCL (1.36B): AI-driven antibody @hypergrowth102 Based on current market data (as of July [--] 2025) only [--] from the list have market caps under $2B. Here they are with competitive advantages: [--]. PRME (0.53B): Prime gene editing technology. [--]. OUST (1.21B): Cost-effective digital lidar. [--]. ABCL (1.36B): AI-driven antibody"
X Link 2025-08-01T06:51Z [---] followers, [---] engagements

"@jrouldz I expect that $ABCL will be next 🔥 with business model and technology. Maybe today after earnings 🤔 My first position of $PLTR is from 2021"
X Link 2025-08-06T21:48Z [---] followers, [---] engagements

"$ABCL Q2 [----] Results & Business Highlights Reported Earnings and Financials: Revenue: $17.1 million in Q2 [----] up significantly from $7.3 million in Q2 2024a remarkable 135% YoY increase. Net Loss: $34.7 million slightly improved from $36.9 million in Q2 [----]. ++"
X Link 2025-08-07T20:35Z [---] followers, [----] engagements

"The company dramatically outperformed expectations on the top line exceeding even the higher $7.55M estimates by a substantial margin. While EPS wasnt disclosed in the Business Wire release improved net loss compared to the prior year suggests progress"
X Link 2025-08-07T20:37Z [---] followers, [--] engagements

"Investor Takeaways [--]. Positive Momentum and Credibility The surge in revenue validates AbCelleras hybrid strategy and platform monetization. Launching two Phase [--] trials and advancing a third asset is a major clinical credibility milestone"
X Link 2025-08-07T20:37Z [---] followers, [---] engagements

"2. Pipeline Optionality With [--] clinical-stage assets and strong liquidity AbCellera now balances platform services with actual drug development upside. Developments may reframe investor expectationsfrom speculative biotech to emerging royalty and pipeline-driven value"
X Link 2025-08-07T20:38Z [---] followers, [---] engagements

"🚨 $ABCL Earnings Q2 [----] 🚨 Revenue: $17.1M (vs. $7.5M est) ✅ Net loss: $34.7M (improving YoY) [--] Phase [--] trials started (ABCL-635 ABCL-575) [--] clinical molecules (+29% YoY) $750M cash on hand 💰 🔬 Transition to full clinical-stage biotech underway. #ABCL"
X Link 2025-08-07T20:43Z [---] followers, [----] engagements

"@DrTomsLens I believe Nov [--] will surprise to the upside. With AbbVies renewed commitment + ABCLs strong cash position I expect earnings to beat expectations"
X Link 2025-08-17T17:14Z [---] followers, [---] engagements

"@JackPrescottX @Jaycarriage Hi Jack Here you can find the summary and script https://www.investing.com/news/transcripts/abcellera-at-wells-fargo-conference-strategic-pipeline-expansion-93CH-4227156 https://www.investing.com/news/transcripts/abcellera-at-wells-fargo-conference-strategic-pipeline-expansion-93CH-4227156"
X Link 2025-09-05T19:33Z [---] followers, [---] engagements

"Dr. Sarah Noonberg at $ABCL Upcoming Catalysts: Adds credibility ahead of Morgan Stanley/HF conferences. Valuation Upside: Bolsters case for re-rating from platform story to clinical execution. Risk Mitigation: Strong leadership reduces perceived clinical and regulatory risk. AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer https://t.co/m4e8dftMyD https://t.co/Wkb94XFu5L AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer https://t.co/m4e8dftMyD https://t.co/Wkb94XFu5L"
X Link 2025-09-10T22:32Z [---] followers, [---] engagements

"TL;DR: Hiring Dr. Noonberg is more than filling a role. Its a beacon signaling AbCelleras clinical evolution. It adds tangible credibility execution prowess and investor comfortespecially if upcoming investor events confirm pipeline momentum. $ABCL"
X Link 2025-09-10T22:32Z [---] followers, [---] engagements

"📈 Following $ABCL for months w/ deep dives (cash runway AbbVie deals insider holders like Peter Thiel/Renaissance). ✅ Support $4 ✅ Breakout setup toward $67 ✅ Short interest still high = squeeze potential Nov [--] earnings + new CMO hire could re-rate $ABCL 👇"
X Link 2025-09-13T06:43Z [---] followers, [----] engagements

"💰 Earnings Nov 11: Management already said runway is 3+ years w/o dilution. Revenues from research fees + potential AbbVie upfront/milestones could surprise to the upside. Consensus is low = setup for a beat. #ABCL"
X Link 2025-09-13T06:44Z [---] followers, [---] engagements

"🤝 AbbVie isnt just a molecule partner theyve got access to AbCelleras whole discovery engine. Like ASML in chips or Apples App Store: platform leverage creates stickiness. Renewals multi-program scope oncology focus = long-term moat"
X Link 2025-09-13T06:44Z [---] followers, [---] engagements

"@cevikfinance $ABCL ve iShares Physical Silver ETF"
X Link 2025-09-15T07:34Z [---] followers, [---] engagements

"🌐 Partnerships matter. $ABCL isnt a single-asset play AbbVie Regeneron & others leverage its antibody discovery platform. Each renewal = validation + potential milestone/royalty streams. Think antibody factory business model"
X Link 2025-09-21T23:16Z [---] followers, [---] engagements

"🧬 Pipeline heating up: ABCL635: first patient dosed ABCL575: Phase [--] ongoing ABCL688: IND-ready Multiple shots on goal more catalysts ahead. Success in even one high-value indication could transform revenue trajectory"
X Link 2025-09-21T23:17Z [---] followers, [--] engagements

"📅 Near-term catalysts: Wells Fargo HC Conf (Sept 5) Morgan Stanley Global HC Conf (Sept 8) Next earnings: Nov [--] Institutions are watching closely. Strong updates could trigger insti re-rating + more attention on $ABCLs long-term TAM"
X Link 2025-09-21T23:17Z [---] followers, [---] engagements

"$ABCL deep-dive (Sept [----] report): AI antibody discovery platform $600M+ cash no debt [--] clinical programs 100+ partner projects Price now $4.67 target $46.76 (+750% in [--] yrs) Speculative BUY 🚀 High risk reward. Catalysts: collabs Ph1/2 data AbbVie"
X Link 2025-09-26T17:21Z [---] followers, [---] engagements

"@DrTomsLens $ABCL has shades of both. Like $PLTR its a platform play monetizing discovery for dozens of partners while building a proprietary data/AI moat. Like $TSLA its also taking shots at its own pipeline trying to prove its tech works end-to-end and capture outsized upside"
X Link 2025-10-01T21:19Z [---] followers, [---] engagements

"@ironman20054 Could it be Christian Angermayer who invested during IPO in [----] with Peter Thiel https://www.manager-magazin.de/finanzen/artikel/peter-thiel-und-christian-angermayer-investieren-in-coronavirus-antikoerper-a-1307336.html https://www.manager-magazin.de/finanzen/artikel/peter-thiel-und-christian-angermayer-investieren-in-coronavirus-antikoerper-a-1307336.html"
X Link 2025-10-09T20:10Z [---] followers, [---] engagements

"$ABCL The misunderstood AI biotech moat 💥 Most investors avoid biotech. But AbCellera isnt your average bet its building infrastructure not chasing blockbusters. Heres why it stands out in 2025: 🧵👇"
X Link 2025-10-15T21:34Z [---] followers, [---] engagements

"4/ 💉 Emerging pipeline ABCL635 (hot flashes) Phase [--] ABCL575 (OX40L engager) clinic-ready [--] molecules in clinic across [--] programs"
X Link 2025-10-15T21:35Z [---] followers, [--] engagements

"5/ 💥 The play AI + wet lab + partner leverage Diversified bets Defensible IP Infrastructure not a one-shot drug gamble Is Wall Street sleeping on $ABCL 👀 #Investing #Biotech #AI #ABCL"
X Link 2025-10-15T21:36Z [---] followers, [--] engagements

"@hypergrowth102 Do you think that $ABCL stock gets higher due to short squeeze or the facility investments are completed and products are ready for market"
X Link 2025-07-24T13:47Z [---] followers, [---] engagements

"https://www.moomoo.com/news/post/58549087/we-think-abcellera-biologics-nasdaq-abcl-can-easily-afford-to https://www.moomoo.com/news/post/58549087/we-think-abcellera-biologics-nasdaq-abcl-can-easily-afford-to"
X Link 2025-09-21T23:14Z [---] followers, [---] engagements

"@jinseongeo83473 @jjacobpeterson Thats correct. Latest report of institutions: Selling 70% of Goldmans position signals reduced confidence or reallocation. But the stake was small in value ($190K post-sale) UBS Northern Trust Squarepoint all increased positions. The net institutional flow still positive"
X Link 2025-09-29T08:15Z [---] followers, [---] engagements

"🚩 $ABCL setting up a classic bull flag 📈 Pole: $3.66 $6.50 📉 Flag: Consolidation $5.50$6.50 🎯 Breakout target: $9.30+ ✅ Holding 50/100/200 MA 🔥 Volume fading = textbook setup 👀 Watching for $6.50 breakout confirmation #ABCL #biotech #stocks #bullflag #TA"
X Link 2025-10-22T06:48Z [---] followers, [---] engagements

"$ABCL @alc2022 your thesis and research on $ABCL AbCellera is mentioned (and you by name) in this Yahoo Finance article Antonio: https://t.co/rfqGgqTX5W @alc2022 your thesis and research on $ABCL AbCellera is mentioned (and you by name) in this Yahoo Finance article Antonio: https://t.co/rfqGgqTX5W"
X Link 2025-10-22T11:23Z [---] followers, [---] engagements

"🧬 $ABCL is entering a loaded catalyst window in NovDec [--] major investor conferences ahead potential for visibility partnerships & fund attention. Lets break down what to watch 👇 #ABCL #biotech #stocks"
X Link 2025-10-29T12:51Z [---] followers, [---] engagements

"📅 Upcoming events: Nov [--] Truist BioPharma Symposium early read on sector sentiment Nov 11-13 Stifel Healthcare fireside chats w/ analysts Nov 18-20 Jefferies Global HC potential fund exposure Dec 2-4 Piper Sandler HC year-end positioning 🔥"
X Link 2025-10-29T12:51Z [---] followers, [--] engagements

"Why it matters: 💡 Each event = chance to spotlight AbCelleras platform 💰 Renewed fund interest + short pressure easing 📈 If momentum continues breakout above $6+ could confirm the trend Stay tuned November might be busy for $ABCL 👀"
X Link 2025-10-29T12:51Z [---] followers, [---] engagements

"$ABCL isnt a high-risk biotech its a platform company quietly building the infrastructure for next-gen antibody discovery. Not betting on [--] drug. Its scaling a discovery engine that feeds itself: data AI better antibodies more data. 👇 https://www.reddit.com/r/ABCL/s/3dJdQzLcxT https://www.reddit.com/r/ABCL/s/3dJdQzLcxT"
X Link 2025-10-30T17:23Z [---] followers, [---] engagements

"Most still price $ABCL like a binary biotech. But risk here = execution not survival. ✅ 96+ partner programs ✅ [--] in clinic ✅ Strong cash runway ✅ Growing AI-microfluidics edge When the first big royalty hits the market re-rates overnight. #ABCL #biotech #AI #investing"
X Link 2025-10-30T17:23Z [---] followers, [---] engagements

"$5.42 is a crucial support holding here could confirm the next leg up. The trend still looks bullish on the weekly. Watching for confirmation this week. 💡📈 $ABCL"
X Link 2025-10-30T18:27Z [---] followers, [----] engagements

"Strategic Direction (20262030) $ABCL: Evolution toward hybrid model leveraging its discovery engine as a royalty-backed SaaS for antibodies while incubating [--] internal candidates to Phase [--]. 👇 https://open.substack.com/pub/seahorseinvest/p/abcl-abcellera-vs-rxrx-recursionutm_campaign=post&utm_medium=web https://open.substack.com/pub/seahorseinvest/p/abcl-abcellera-vs-rxrx-recursionutm_campaign=post&utm_medium=web"
X Link 2025-11-02T17:08Z [---] followers, [---] engagements

"Expect deeper integration of ML-guided developability metrics and broader immune-target portfolios (NK GPCR ion channels). $ABCL (AbCellera) vs RXRX (Recursion) - Biotechs Data War Antibodies vs Algorithms"
X Link 2025-11-02T17:10Z [---] followers, [---] engagements

"@Jare92365776 In AbCelleras presentation at a healthcare conference they mentioned that Bayer and Astellas will go first and help build the market awareness in the context of the menopause space. Do they have a formal partnership $ABCL"
X Link 2025-11-02T17:35Z [---] followers, [---] engagements

"🔍 [--] The Core Insight AbCellera ( $ABCL ) is ranked as the top Leader in the biologics discovery space with a score of 9.7/10 placing it ahead of AbSci (8.7) Generate Biomedicines and BigHat Biosciences. 👇 New CBI Report Published 12/9 showing $ABCL the runaway leader for the category of " #AI in biologics discovery proteins" The AI in biologics discovery proteins market focuses on companies developing novel protein therapeutics through AI-enabled design and optimization. https://t.co/R2pz3yzxl6 New CBI Report Published 12/9 showing $ABCL the runaway leader for the category of " #AI in"
X Link 2025-11-03T08:20Z [---] followers, [----] engagements

"This means: AbCellera is not only considered a technological leader but also has strong market execution (top-right quadrant). Its execution strength (delivery reliability and partnerships) is viewed as the best in class. 👇"
X Link 2025-11-03T08:20Z [---] followers, [---] engagements

"What Drives AbCelleras Leadership CB Insights credits $ABCL for: A success-based business model (milestone & royalty-driven) that aligns incentives with partners minimizing risk and maximizing trust. ++👇"
X Link 2025-11-03T08:20Z [---] followers, [---] engagements

"$ABCL earnings today 📣 This is not a typical biotech report. Key signals to watch: 🔬 ABCL-635 & ABCL-575 progress 🤝 New partner program starts 💰 Cash runway (no dilution) ⚖ Bruker tone Price is sitting on major support. Hold $6+ Fail retest $3.7 Big day"
X Link 2025-11-06T15:17Z [---] followers, [----] engagements

"Re-test on $ABCL. 📉 Discipline matters: Hold cash for the right add Let trend + indicators guide timing And yes if support breaks you sell This isnt emotional investing. Its position building + protection. $ABCL earnings today 📣 This is not a typical biotech report. Key signals to watch: 🔬 ABCL-635 & ABCL-575 progress 🤝 New partner program starts 💰 Cash runway (no dilution) ⚖ Bruker tone Price is sitting on major support. Hold $6+ Fail retest $3.7 Big day. $ABCL earnings today 📣 This is not a typical biotech report. Key signals to watch: 🔬 ABCL-635 & ABCL-575 progress 🤝 New partner"
X Link 2025-11-07T18:17Z [---] followers, [---] engagements

"@sotirou32933 @Jare92365776 High short interest + low volume doesnt mean buy tomorrow. It means ABCL is mispriced under skepticism and any real progress can reprice it violently"
X Link 2025-12-27T22:28Z [---] followers, [--] engagements

"$ABCL chart is tightening near key resistance ($5.5) while holding higher-low structure. This comes ahead of a major catalyst: 🗓 JPM Healthcare Conference Jan [--] [----] Thats where institutional narratives shift"
X Link 2026-01-05T23:43Z [---] followers, [---] engagements

"Technically ABCL is stabilizing after a long reset: Below short/mid-term MAs Holding a consolidation range Limited downside follow-through despite weak sentiment That usually signals time risk downside risk"
X Link 2026-01-06T14:20Z [---] followers, [---] engagements

"Why Phase [--] matters: Phase [--] is where biotech valuation starts to decouple from cash value. Youre no longer betting on can this reach humans Youre testing biological relevance + execution quality"
X Link 2026-01-27T10:06Z [---] followers, [---] engagements

"Whats easy to miss: Alongside clinical progress ABCL disclosed that: Platform investments are completed Clinical manufacturing activities have started Trials are described as on track Thats infrastructure not hype"
X Link 2026-01-27T10:06Z [---] followers, [---] engagements

"Partnership Expansion & Pipeline Growth: Partner-initiated programs with downstream continuation rose from [--] to 102a 10% increase over the year. Molecules in the clinic expanded from [--] to [--] a 29% growth"
X Link 2025-08-07T20:36Z [---] followers, [---] engagements

"Strategic Remarks: CEO Carl Hansen emphasized that dosing initiation marks the companys full transition into a clinical-stage biotech. AbCellera holds over $750 million in liquidity ensuring substantial runway to advance its internal pipeline"
X Link 2025-08-07T20:36Z [---] followers, [---] engagements

"💡 $ABCL update: Cash runway looks 🔥 $553M cash debt-free Burning $139M/year [--] years runway Cash burn down 19% YoY Analysts see breakeven soon Burn = 10% of market cap low dilution risk Strong balance sheet + discipline = grow without heavy dilution"
X Link 2025-09-21T23:13Z [---] followers, [---] engagements

"@ProfKayaFinance Biyoteknoloji konusunda $ABCL firmasn takip ediyorum. 350$ maliyetli en byk pozisyonum. 40$ IPO dan 2$ dibe oradan 510$ ve 590$ grdkten sonra 360$ la [----] ya giri yapyor. Carl Hansen end to end tesisi tamamlad ekibi geniletti ve [----] Q3 e gl 💪 giriyor"
X Link 2025-12-21T11:52Z [---] followers, [---] engagements

"$ABCL is no longer a momentum trade. At current levels the chart suggests a base-building / accumulation phase low expectations compressed price action and patience required. This is about positioning not short-term speculation"
X Link 2026-01-06T14:20Z [---] followers, [---] engagements

"$ABCL will discuss: [----] pipeline priorities ABCL635 (Phase [--] readout expected in 2026) ABCL575 (Phase [--] / partnering path) Platform strategy post-IP overhang Stocks rarely move during JPM moves often come weeks later"
X Link 2026-01-06T14:20Z [---] followers, [---] engagements

"Most recently the 3-month return stands at -30.5% capping a period marked by deep volatility and persistent underperformance relative to its post-IPO highs. #TechnicalAnalysis #StockAnalysis #Investingcom https://www.investing.com/warrenai/share/3776ece4-4289-4b19-b14c-360c3f2dedb0_d310a40483f9399dd7ed1712e0fdd702 https://www.investing.com/warrenai/share/3776ece4-4289-4b19-b14c-360c3f2dedb0_d310a40483f9399dd7ed1712e0fdd702"
X Link 2026-01-09T06:51Z [---] followers, [--] engagements

"$ABCL reports FY2025 results on Feb [--] [----]. This isnt about near-term revenue its about execution of the shift from discovery platform integrated biopharma. Key context: internal clinical assets IP clarity and infrastructure build-out. 👇"
X Link 2026-01-23T06:31Z [---] followers, [----] engagements

"Whats changed recently $ABCL: New CMO Sarah Noonberg (clinical execution) Co-founder Stephen Quake still anchoring the microfluidics moat Bruker IP dispute resolved ($36M + royalties) Internal assets now Phase 1/2 (ABCL635 ABCL575)"
X Link 2026-01-23T06:31Z [---] followers, [---] engagements

"Holders matter too. $ABCL ABCL has long-duration platform-oriented backers incl. Founders Fund (Peter Thielaffiliated) and DCVC plus institutions that stayed through volatility. Not a binary biotech. Execution + time into [----] is the real story"
X Link 2026-01-23T06:31Z [---] followers, [---] engagements

"$ABCL is often framed as cash + platform optionality. But JPM [----] disclosures suggest a quieter shift: AbCellera is now a multi-program clinical biotech not just a discovery engine. Heres the setup 👇 Company: AbCellera"
X Link 2026-01-27T10:06Z [---] followers, [---] engagements

"@ulkser unu paylamak isterim Serkan Bey Cazip Hisseler videosu ile satn alm olduum kkl firmalar ISBANK YKB EREGL ULKER ALARKO vb hisselerim %18 (%10 ile %46 aras) artda. Ayn anda aldm BIST30 temelli Ziraat ZPX30 hisse senedi %23 artda. Az zahmet benzer getiri"
X Link 2026-01-29T10:08Z [---] followers, [---] engagements

"EURO kullanan lkelerde yatrm yaptnzda son [--] ylda aadaki gibi USD/EUR kur farkn hissediyorsunuz. Kur sabit kalsa portfy EURO baznda yaklak %15 byyebilirdi. [---] lere giderse sevindirir @TuncSatiroglu @cevikfinance"
X Link 2026-01-29T18:25Z [---] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing